Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | BCL9 | O00512 | 6/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24872977 | 0.81 | REN (0.57) | RENSLC6A2SLC6A4KCNH2CYP3A4 | |
| SCHEMBL31258379 | 0.76 | REN (0.58) | RENSLC6A2SLC6A4BCL9CTNNB1 | |
| SCHEMBL13625495 | 0.74 | SLC6A2 (0.60) | RENSLC6A2SLC6A4KCNH2CYP3A4 | |
| SCHEMBL13625563 | 0.70 | SLC6A4 (0.51) | RENSLC6A2SLC6A4KCNH2CYP3A4 | |
| SCHEMBL31258387 | 0.69 | REN (0.53) | RENBCL9CTNNB1 | |
| SCHEMBL24873100 | 0.69 | REN (0.53) | RENBCL9CTNNB1 | |
| SCHEMBL13625727 | 0.69 | REN (0.68) | RENKCNH2CYP3A4 | |
| SCHEMBL31258384 | 0.69 | GPR88 (0.43) | RENBCL9CTNNB1KCNH2OPRM1 | |
| SCHEMBL1911550 | 0.68 | REN (1.00) | RENKCNH2 | |
| SCHEMBL13625719 | 0.67 | REN (0.60) | RENKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | Nantong Jutai Biotech Co., Ltd. (CN) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | BCL9, BCL9L, BCL2L11 | REN 1371/4885SLC6A2 3905/4885SLC6A4 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.